Kia Cuts EV Prices in Europe as Chinese Carmakers Intensify Competition 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Google Secures Pentagon AI Deal for Classified Projects 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
PHOENIX, Feb. 10, 2016 -- Insys Therapeutics, Inc. (“Insys” or “the Company”) (NASDAQ:INSY) today announced that Santosh Vetticaden, MD, PhD, Chief Medical Officer, and Darryl Baker, Chief Financial Officer, will present at the RBC Capital Markets 2016 Global Healthcare Conference as follows:
| Date: | Wednesday, February 24, 2016 | |
| Time: | 8:30 a.m. Eastern Standard Time | |
| Location: | The New York Palace Hotel, NYC | |
The presentation will be webcast live at http://www.veracast.com/webcasts/rbc/healthcare2016/32202255515.cfm at the aforementioned time as well as archived for 90 days thereafter on the Company’s website at www.insysrx.com, under the Investors Section.
About Insys Therapeutics, Inc.
Insys Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve the quality of life of patients. Using proprietary sublingual spray technology and capabilities to develop pharmaceutical cannabinoids, Insys addresses the clinical shortcomings of existing commercial products. Insys currently markets one product: Subsys® (fentanyl sublingual spray). The Company recently submitted a New Drug Application to the U.S. Food and Drug Administration for Syndros® (dronabinol oral solution), a proprietary, orally administered liquid formulation of dronabinol that Insys believes has distinct advantages over the current formulation of dronabinol in soft gel capsule. Insys is developing a pipeline of sublingual sprays, as well as pharmaceutical cannabidiol.
Subsys® and Syndros® are registered trademarks of Insys Therapeutics, Inc.
Investor Contact: Lisa M. Wilson, President In-Site Communications, Inc. Phone: 212-452-2793 Email: [email protected]
